Overview

Everolimus on CKD Progression in ADPKD Patients

Status:
Terminated
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The study will evaluate whether the administration of everolimus (1.5 mg/day) can slow down the progression of CKD in ADPKD patients.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
A. Manzoni Hospital
Treatments:
Everolimus
Sirolimus